US Pharma MarketingCelcuity wins approval for breast cancer drug Revtorpyk
Celcuity Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
A small public biotech won approval for a breast cancer drug that was designed to improve on similar treatments from Novartis and Roche.
The FDA on Tuesday cleared Celcuity's Revtorpyk in combination with fulvestrant, with ...
Source: Endpoints News